Our Story
In the summer of 2019, a close friend's cat was diagnosed with Feline Infectious Peritonitis.
She loved that cat the way most people love family. When three separate veterinarians told her that FIP was untreatable — that the best they could offer were steroids to slow the suffering — she was devastated. Not because she had run out of options, but because she had been told there were none.
[We knew that wasn't entirely true.]
At the time, emerging research on a compound called GS-441524 was showing remarkable results in cats with FIP. The science was there. The outcomes were documented. But access was fragmented, information was scattered across closed online communities, and cat owners in crisis had no reliable, trusted source to turn to.
[We decided to change that.]
CureFIP™ was founded the in August of that year to do one thing: make clinically effective FIP treatment accessible to every cat owner who needed it, regardless of where they lived. We built direct-to-consumer access at a time when most cat owners had never heard of GS-441524 and most veterinarians had no way to prescribe it.
What started as one product serving one community has grown into a comprehensive treatment platform — GS-441524 injectables and oral capsules, EIDD-1931 protocols, and organ-supportive formulations — trusted by cat owners and veterinarians across 50+ countries. To date, CureFIP™ treatments have contributed to the recovery of over 87,000 cats worldwide.
CureFIP™ is backed by a GMP-certified manufacturing facility and operated by a team with deep expertise in veterinary pharmaceutical development, regulatory compliance, and cross-border distribution. We are not a pharmacy. We are not a charity. We are a company that built real infrastructure around a real problem — because that is the only way to solve it at scale.
The Science Behind CureFIP™
The Discovery of GS-441524
The use of GS-441524 to treat feline infectious peritonitis was discovered by a research team led by Dr. Niels Pedersen at the University of California, Davis — one of the world's leading authorities on feline viral diseases.
Early clinical trials established what is now well-documented: GS-441524 achieves remission rates exceeding 80% across all forms of FIP. In the rare cases where relapse occurred — fewer than 10% of treated cats — the drug proved equally effective in subsequent treatment courses. No resistance ceiling. No diminishing returns.
For a disease that had been considered universally fatal for decades, this was not an incremental improvement. It was a categorical shift in what was possible.
